Alcon
Alcon, the world’s leading eye care company, signed a collaboration and licensing agreement with NovaBay in August 2006. Alcon and NovaBay will work together to research, develop and commercialize NovaBay’s Aganocide compounds to treat infections of the eye, ear and sinus, including those associated with persistent bacterial biofilm.
July 5, 2009
Alcon Commences Phase 2 Clinical Trial of NovaBay’s NVC-422 for Viral Conjunctivitis
September 18, 2006
NovaCal Licenses Novel Anti-Infective Compounds for Eye, Ear and Sinus Infections to Alcon
